CLR 131 Achieves 50% Overall Response Rate in Cohort 6 of Ongoing Phase 1 Study in Relapsed or Refractory Multiple Myeloma May 15, 2019
Cellectar Receives FDA Fast Track Designation for CLR 131 in Relapsed or Refractory Multiple Myeloma May 13, 2019
FDA Grants Exemption to Import Alert for Cellectar’s CLR 131 in Pediatric and Adolescent Patients Mar 19, 2019
Cellectar Reports Financial Results for Year Ended December 31, 2018 and Provides a Corporate Update Feb 26, 2019
Cellectar Reports Positive Top-line Response Rate of 30% from R/R Multiple Myeloma Cohort in Ongoing Phase 2 Study of CLR 131 Feb 25, 2019
Cellectar Biosciences to Present at NobleConXV, Noble Capital Markets’ Fifteenth Annual Investor Conference Jan 23, 2019
Cellectar Provides Update on Phase 1 Trial of CLR 131 in Relapsed/Refractory Multiple Myeloma Jan 7, 2019
